Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cardiac Resynchronization Therapy · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Cardiac Resynchronization Therapy | DEVICE | - |
Inclusion Criteria: * Have an approved indication for implantation of an ICD. * Have advanced HF with a New York Heart Association (NYHA) Classification of III, despite receiving optimal pharmacological therapy. * Have a stable heart failure medical regimen. * Have a left ventricular ejection fract...
Top 20 of 31 competitors
Cardiac Resynchronization Therapy is a treatment evaluated for heart failure. It involves pacing to coordinate heart contractions and is being studied in patients with this condition. The therapy is currently in Phase 3 clinical development.
Cardiac Resynchronization Therapy is developed by Abbott Laboratories, a company traded on the stock exchange under the ticker ABT. Abbott is conducting clinical research on this therapy for heart failure.
Cardiac Resynchronization Therapy is in Phase 3 clinical development. It is an investigational therapy for heart failure and has not been reported as approved by regulatory authorities.
Cardiac Resynchronization Therapy is being studied in the RethinQ Study, identified as NCT00132977. This Phase 3 trial enrolled 250 participants with heart failure in the United States and has been completed.
Cardiac Resynchronization Therapy is a form of pacing evaluated for heart failure. The RethinQ Study, NCT00132977, assessed pacing in heart failure patients, indicating that the therapy involves pacing as part of its approach.